Abstract
We discovered a novel heterobiaryl pyrazolopyridine skeleton as a selective FLT3 inhibitor from phenotype-based viability profiling and hypothesis-driven deconvolution.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have